Business Context and Reporting Period
Company: Alterity Therapeutics Ltd
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: August 2020 (Filed August 4, 2020)
Principal Executive Office: Melbourne, VIC, Australia
This filing incorporates by reference an Appendix 4C and Quarterly Cash Flow Report filed on July 30, 2020. It also includes a Notice of General Meeting.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. It references a Quarterly Cash Flow Report filed on July 30, 2020, but does not reproduce the data within this document.
Material Changes and Compliance Status
- NASDAQ Compliance Regained: On July 15, 2020, NASDAQ notified the Company that it regained compliance with the minimum bid price requirement of Listing Rule 5550(a)(2).
- Previous Deficiency: On February 5, 2020, the Company was notified that its ADSs failed to maintain a minimum bid price of $1.00 over 30 consecutive business days, triggering a 180-day compliance period.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, financial guidance, outlook, or specific risk factors beyond the resolution of the NASDAQ listing compliance issue.
Investor Verification Checklist
- Verify the specific cash flow figures in the Appendix 4C and Quarterly Cash Flow Report filed on July 30, 2020, as they are referenced but not detailed here.
- Confirm the details of the Notice of General Meeting referenced in Item 99.1.
- Monitor the stock price to ensure continued compliance with the $1.00 minimum bid price requirement.